title: Chronic unpredicted mild stress-induced depression alter saxagliptin pharmacokinetics and CYP450 activity in GK rats.
abstract: Background. This study was to explore the pharmacokinetics of saxagliptin (Sax) in Goto-Kakizaki (GK) rats complicated with depression induced by chronic unpredicted mild stress (CUMS). The comorbidity of diabetic patients with depression is becoming more and more epidemic. Whether depression mental disorder alters the pharmacokinetics of hypoglycemic drugs in diabetes patients is not clear. Methods. Five-week-old male GK rats were kept in the cage for 7 weeks in a specific pathogen free (SPF)-grade lab until the emergence of diabetes and were then divided into two groups: control group and depression model group. Rats in the CUMS-induced depression group were exposed to a series of stressors for 8 weeks. Plasma serotonin and dopamine levels and behavior of open-field test were used to confirm the establishment of the depression model. All rats were given 0.5 mg/kg Sax orally after 8 weeks and blood samples were collected at different time points. The Sax concentration was assayed by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The CYP450 activity of the liver microsomes was determined by using cocktails of probe drugs in which the activities of CYP enzymes were assessed through the determination of the production of the probe drugs. Results. Statistically significant differences in Sax pharmacokinetics were observed for area under curve, clearance, peak concentration, peak time and mean residence time between the depression rats and the control rats, while no statistical differences were observed for half-time and distribution volume by HPLC-MS/MS analysis. The CYP450 activity had different changes in the depression group. Conclusions. These results indicated that CUMS-induced depression alters the drug metabolic process of Sax and CYP450 activity of the liver microsomal enzymes in GK rats.
authors.affiliation: Department of Pharmacy, Fengxian Central Hospital Graduate Training Base, Liaoning Medical University , Shanghai , China.
authors.forename: Zhengchao
authors.initials: Z
authors.lastname: Xia
authors.affiliation: Department of Pharmacy, Southern Medical University Affiliated Fengxian Central Hospital , Shanghai , China.
authors.forename: Hongyan
authors.initials: H
authors.lastname: Wei
authors.affiliation: Department of Pharmacy, Southern Medical University Affiliated Fengxian Central Hospital , Shanghai , China.
authors.forename: Jingjing
authors.initials: J
authors.lastname: Duan
authors.affiliation: Department of Pharmacy, Southern Medical University Affiliated Fengxian Central Hospital , Shanghai , China.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.affiliation: Department of Pharmacy, Fengxian Central Hospital Graduate Training Base, Liaoning Medical University , Shanghai , China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Yang
authors.affiliation: Department of Pharmacy, Fengxian Central Hospital Graduate Training Base, Liaoning Medical University, Shanghai, China; Department of Pharmacy, Southern Medical University Affiliated Fengxian Central Hospital, Shanghai, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
keywords: CUMS; Depression; Diabetes; Pharmacokinetics; Rat; Saxagliptin
references.citation: PLoS One. 2013;8(3):e57058
references.pmid: 23472075
references.citation: Eur J Pharmacol. 2015 May 15;755:42-9
references.pmid: 25720341
references.citation: Neurosci Biobehav Rev. 1981 Summer;5(2):247-51
references.pmid: 7196554
references.citation: Headache. 2012 Apr;52(4):600-11
references.pmid: 22077836
references.citation: Drug Metab Dispos. 2009 Jun;37(6):1164-71
references.pmid: 19251818
references.citation: Psychopharmacology (Berl). 1991;104(2):255-9
references.pmid: 1876670
references.citation: Synapse. 2015 Sep;69(9):453-60
references.pmid: 26089169
references.citation: Expert Opin Drug Saf. 2015 Apr;14(4):505-24
references.pmid: 25630605
references.citation: Sci Rep. 2014 Jan 21;4:3794
references.pmid: 24445843
references.citation: Toxicol Lett. 2014 Aug 17;229(1):33-40
references.pmid: 24910189
references.citation: World Psychiatry. 2015 Feb;14(1):15-26
references.pmid: 25655145
references.citation: Diabetes Res Clin Pract. 2010 Mar;87(3):302-12
references.pmid: 20181405
references.citation: Diabetes Care. 2015 Apr;38(4):696-705
references.pmid: 25552421
references.citation: Eur J Clin Pharmacol. 2014 Aug;70(8):933-40
references.pmid: 24858822
references.citation: Expert Opin Drug Saf. 2014 Sep;13 Suppl 1:S57-68
references.pmid: 25171159
references.citation: J Med Chem. 2005 Jul 28;48(15):5025-37
references.pmid: 16033281
references.citation: Expert Opin Drug Metab Toxicol. 2013 Oct;9(10):1317-34
references.pmid: 23834396
references.citation: Cardiol Rev. 2010 Jul-Aug;18(4):213-7
references.pmid: 20539105
references.citation: Lancet. 2015 May 23;385(9982):2107-17
references.pmid: 26009231
references.citation: Diab Vasc Dis Res. 2015 May;12(3):154-63
references.pmid: 25852133
references.citation: Drug Metab Rev. 2013 May;45(2):253-75
references.pmid: 23590174
references.citation: Gen Hosp Psychiatry. 2015 Sep-Oct;37(5):420-6
references.pmid: 26094130
references.citation: Biomed Chromatogr. 2012 Dec;26(12):1482-7
references.pmid: 22334441
references.citation: Diabetes Obes Metab. 2015 Jul;17(7):630-8
references.pmid: 25761977
references.citation: Neurosci Biobehav Rev. 1981 Summer;5(2):253-8
references.pmid: 7196555
references.citation: J Med Internet Res. 2015 Feb 26;17(2):e55
references.pmid: 25803420
references.citation: Psychopharmacology (Berl). 1997 Dec;134(4):319-29
references.pmid: 9452163
references.citation: Eur Rev Med Pharmacol Sci. 2012 Apr;16(4):427-36
references.pmid: 22696869
references.citation: Eur J Pharmacol. 2015 Mar 15;751:34-41
references.pmid: 25637782